ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Size, Share and Growth Outlook, 2026

ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global ERCP (Endoscopic Retrograde Cholangiopancreatography) Market size is forecast to increase from $2.03 Billion in 2026 to $4.02 Billion in 2034 at a CAGR of 8.9% between 2026 and 2034.

The ERCP (Endoscopic Retrograde Cholangiopancreatography) market report provides detailed analysis and outlook of ERCP (Endoscopic Retrograde Cholangiopancreatography) segments including By Product (Duodenoscopes, Endotherapy Devices, Stents, Visualization & Imaging Systems, Energy Devices, Accessories & Consumables), By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilatation), By Technology (Reusable Systems, Hybrid Systems, Fully Single-Use Systems), By Application (Biliary Disorders, Pancreatic Disorders), By End User (Hospitals, Ambulatory Surgical Centers, Specialty & GI Clinics) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Endoscopic Retrograde Cholangiopancreatography (ERCP) Industry Overview

Rising Focus on ERCP Safety, Advanced Energy Technologies, and Stent-Based Interventions

The Endoscopic Retrograde Cholangiopancreatography (ERCP) industry continues to evolve through advancements in endoscope safety, therapeutic energy delivery systems, and biliary intervention technologies. Increasing demand for minimally invasive diagnosis and treatment of pancreaticobiliary disorders is driving healthcare providers to adopt innovative ERCP platforms that improve procedural precision while reducing complications. Industry participants are focusing on infection prevention, enhanced tissue management, advanced stenting techniques, and optimized procedural workflows to strengthen outcomes in complex biliary and pancreatic interventions.

Enhanced Duodenoscope Reprocessing Standards Strengthening ERCP Infection Control

Patient safety remains a critical priority within the ERCP market. Olympus Corporation implemented an urgent global Field Safety Corrective Action (FSCA) covering its legacy reusable duodenoscope platforms, including the TJF-Q190V and TJF-Q290V models widely utilized in ERCP procedures. The updated protocols introduce rigorous handling requirements, validation procedures, enhanced mechanical reprocessing workflows, and dedicated drying cabinet processes designed to eliminate microbial retention and reduce bio-contamination risks. These strengthened reprocessing standards reflect the industry's growing emphasis on infection control, regulatory compliance, and safe reuse of complex endoscopic devices.

Advanced Energy Platforms Expanding Therapeutic ERCP Capabilities

Technological innovation is transforming therapeutic endoscopy procedures. Creo Medical Group plc reported clinical validation progress for its CROMA advanced energy platform within interventional endoscopy applications. The system combines high-frequency microwave energy and advanced bipolar radiofrequency energy through single-use instruments specifically designed for endoscopic procedures. During complex ERCP and transpapillary stenting interventions, the platform enables biliary endoscopists to perform precise tissue coagulation and immediate hemostasis while maintaining procedural control. The integration of advanced energy modalities into ERCP workflows supports expanded therapeutic capabilities for managing biliary strictures, lesions, and bleeding complications.

Evolving Stent Strategies Driving Procedural Optimization

Clinical research continues to shape stent selection practices in ERCP. A cohort study published in Endoscopy International Open examined procedural risks associated with Self-Expandable Metallic Stents (SEMS). The findings indicated that Fully Covered Self-Expandable Metallic Stents (FCSEMS) used in non-pancreatic cancer indications may increase the likelihood of pancreatic duct orifice obstruction. To address this risk, clinicians are increasingly utilizing specialized 0.025-inch VisiGlide guidewires alongside prophylactic pancreatic stents to reduce the incidence of post-ERCP pancreatitis. These developments highlight the growing importance of device selection, procedural planning, and risk mitigation strategies within advanced ERCP interventions.

ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global ERCP (Endoscopic Retrograde Cholangiopancreatography) market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Fujifilm Holdings Corporation, Medtronic plc, STERIS plc, Merit Medical Systems, TeleMed Systems, KARL STORZ SE & Co. KG. The ERCP (Endoscopic Retrograde Cholangiopancreatography) market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the ERCP (Endoscopic Retrograde Cholangiopancreatography) industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth ERCP (Endoscopic Retrograde Cholangiopancreatography) Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by ERCP (Endoscopic Retrograde Cholangiopancreatography) companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional ERCP (Endoscopic Retrograde Cholangiopancreatography) markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Competitive Benchmarking and Company Analysis

Leading companies in ERCP (Endoscopic Retrograde Cholangiopancreatography) industry include- Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, Cook Medical, Fujifilm Holdings Corporation, Medtronic plc, STERIS plc, Merit Medical Systems, TeleMed Systems, KARL STORZ SE & Co. KG. The ERCP (Endoscopic Retrograde Cholangiopancreatography) market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US ERCP (Endoscopic Retrograde Cholangiopancreatography) Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the ERCP (Endoscopic Retrograde Cholangiopancreatography) market remains one of the strongest-performing segments in the country.
The US ERCP (Endoscopic Retrograde Cholangiopancreatography) Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US ERCP (Endoscopic Retrograde Cholangiopancreatography) market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across ERCP (Endoscopic Retrograde Cholangiopancreatography) industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian ERCP (Endoscopic Retrograde Cholangiopancreatography) markets

Canada's strong ERCP (Endoscopic Retrograde Cholangiopancreatography) sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian ERCP (Endoscopic Retrograde Cholangiopancreatography) market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany ERCP (Endoscopic Retrograde Cholangiopancreatography) Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest ERCP (Endoscopic Retrograde Cholangiopancreatography) market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of ERCP (Endoscopic Retrograde Cholangiopancreatography) population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany ERCP (Endoscopic Retrograde Cholangiopancreatography) industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the ERCP (Endoscopic Retrograde Cholangiopancreatography) market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support ERCP (Endoscopic Retrograde Cholangiopancreatography) sales through 2034

France ERCP (Endoscopic Retrograde Cholangiopancreatography) companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of ERCP (Endoscopic Retrograde Cholangiopancreatography) distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China ERCP (Endoscopic Retrograde Cholangiopancreatography) market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of ERCP (Endoscopic Retrograde Cholangiopancreatography) industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese ERCP (Endoscopic Retrograde Cholangiopancreatography) industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian ERCP (Endoscopic Retrograde Cholangiopancreatography) market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil ERCP (Endoscopic Retrograde Cholangiopancreatography) market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa ERCP (Endoscopic Retrograde Cholangiopancreatography) Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

ERCP (Endoscopic Retrograde Cholangiopancreatography) Market Segmentation

By Product
Duodenoscopes
Endotherapy Devices
Stents
Visualization & Imaging Systems
Energy Devices
Accessories & Consumables
By Procedure
Biliary Sphincterotomy
Biliary Stenting
Biliary Dilatation
Pancreatic Sphincterotomy
Pancreatic Duct Stenting
Pancreatic Duct Dilatation
By Technology
Reusable Systems
Hybrid Systems
Fully Single-Use Systems
By Application
Biliary Disorders
Pancreatic Disorders
By End User
Hospitals
Ambulatory Surgical Centers
Specialty & GI Clinics

Top Companies in ERCP (Endoscopic Retrograde Cholangiopancreatography) Industry

Olympus Corporation
Boston Scientific Corporation
CONMED Corporation
Cook Medical
Fujifilm Holdings Corporation
Medtronic plc
STERIS plc
Merit Medical Systems
TeleMed Systems
KARL STORZ SE & Co. KG

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025